PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33170152-0	2020	S-adenosylmethionine administration inhibits levodopa-induced vascular endothelial growth factor-A expression.	S-Adenosylmethionine	0-20	vascular endothelial growth factor A	Homo sapiens	62-98	
33170152-2	2020	RESULTS: S-adenosylmethionine and levodopa had opposite effects on the protein stability of vascular endothelial growth factor-A.	S-Adenosylmethionine	9-29	vascular endothelial growth factor A	Homo sapiens	92-128	
33170152-7	2020	S-adenosylmethionine could be fitted into the predicted docking pocket in the crystal structure of vascular endothelial growth factor-A, enhancing its acetylation level and reducing half-life.	S-Adenosylmethionine	0-20	vascular endothelial growth factor A	Homo sapiens	99-135	
33170152-8	2020	CONCLUSIONS: These observations suggested that methyl donor S-adenosylmethionine could act as a potential agent against vascular endothelial growth factor-A-related diseases induced by levodopa treatment.	S-Adenosylmethionine	60-80	vascular endothelial growth factor A	Homo sapiens	120-156	
33170152-9	2020	METHODS: We performed in vitro cytological analyses to assess whether S-adenosylmethionine intake could influence levodopa-induced vascular endothelial growth factor-A expression in human umbilical vein endothelial cells.	S-Adenosylmethionine	70-90	vascular endothelial growth factor A	Homo sapiens	131-167